MolecuLight Inc.
12
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.3%
1 terminated/withdrawn out of 12 trials
87.5%
+0.9% vs industry average
0%
0 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Comparing Wound Area Reduction of Non-healing DFUs Using MolecuLight i:X Versus Standard of Care
Role: lead
MolecuLight All-in-One Oxygenation Clinical Utility
Role: lead
Biofilm Correlation and Validation
Role: lead
MolecuLightDX Measurement Feature Clinical Validation
Role: lead
Point-spectroscopy Trial
Role: lead
Presence of Fluorescence Signature to Predict Graft Failure Using MolecuLight i:X
Role: lead
Positive Predictive Value (PPV) of Pseudomonas Aeruginosa
Role: lead
Evaluation of MolecuLight i:X as an Adjunctive Fluorescence Imaging Tool to Clinical Signs and Symptoms for the Identification of Bacteria-containing Wounds
Role: lead
A Prospective Evaluation of Clinical Equivalence Between iX and PID
Role: lead
Positive Predictive Value of the MolecuLight i:X Imaging Device to Predict the Presence of Bacteria in Chronic Wounds
Role: lead
Post Market Clinical Followup of MolecuLight i:X's PPV to Predict Presence of Bacteria in Wounds
Role: lead
A Prospective, Pilot Evaluation of Device Equivalence
Role: lead
All 12 trials loaded